Skip to main content
Fig. 4 | Journal of Biomedical Science

Fig. 4

From: Small heterodimer partner (SHP) aggravates ER stress in Parkinson’s disease-linked LRRK2 mutant astrocyte by regulating XBP1 SUMOylation

Fig. 4

SHP regulates XBP1s SUMOylation through increasing PIAS1 protein stability. A Immunoblotting for PIAS1 in LRRK2-WT and -GS astrocytes treated with cycloheximide (CHX; 100 mg/ml) for up to 8 h. Data are means ± SD of three independent experiments (*p < 0.05). B, C Expression levels of SHP mRNA (B) and proteins (C) were assessed by real-time qPCR and WB, respectively. D LRRK2-GS astrocytes were treated with tunicamycin in the presence or absence of PERK kinase inhibitor (GSK2656157), IRE1 inhibitor (4μ8c), or ATF6 inhibitor (Ceapin-A7). Expression levels of indicated proteins were analyzed by WB. E, F LRRK2-WT and si-SHP–transfected LRRK2-GS astrocytes were treated with tunicamycin and then subjected to immunoprecipitation assay (E) or live/dead assay (F). Three fields of view per group of three independent experiments (n = 9). Scale bar, 100 μm. Data are means ± SD of three independent experiments (*p < 0.05, **p < 0.01)

Back to article page